Videx Use With Zerit May Increase Pancreatitis Risk, Bristol Warns
Executive Summary
The majority of pancreatitis deaths in Videx-treated patients reported to FDA's MedWatch program have been in patients also on Bristol-Myers Squibb's other nucleoside, Zerit (stavudine, d4T), a Bristol "Dear Doctor" letter reports.
You may also be interested in...
Bristol Videx Once-Daily Dosing Restricted After Unfavorable Trial Results
Labeling for Bristol-Myers Squibb's Videx (didanosine) has been revised to recommend against once-daily dosing for most patients following negative findings from a clinical trial using the new 200 mg formulation of the drug.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011